Uni-Bio Science Group Limited is an investment holding company. The Company, along with its subsidiaries is principally engaged in bioscience-related business, which includes research, development and commercialization of biopharmaceuticals through recombinant deoxyribonucleic acid (DNA) and other technologies, and the manufacture, sale and trading of pharmaceutical products. It operates in three segments: Distribution of third party pharmaceutical products, In-house chemical pharmaceutical products and In-house biological pharmaceutical products. The Company鈥檚 products include rExendin-4, rhEPO-Fc, cTP-5, LFA3-Fc, rhIL-11 and rhPTH 1-34. Its rExendin-4 is a non-insulin anti-diabetic treatment candidate that stimulates the incretin pathway. The Company鈥檚 cTP-5 is a chemical drug candidate, which is used for the treatment of chronic hepatitis B. Its LFA3-Fc is a Class I biopharmaceutical candidate for the treatment of psoriasis.